Table 1:

Demographic, clinical, and MR imaging characteristics of the cohort

RRMS (n = 43)SPMS (n = 15)P Valuea
Women (No.) (%)38 (88.4)11 (73.3).658
Age (mean) (SD) (yr)52.8 (12.1)60.5 (6.7).023b
Disease duration (mean) (SD) (yr)15.2 (8.9)21.9 (8.3).014b
EDSS (median) (IQR)3.0 (2.0–3.5)6.0 (3.6–6.5).003b
Age at onset (mean) (SD) (yr)37.6 (12.0)38.7 (8.5).428
Disease-modifying therapy (No.) (%)
    Interferon β-1a I.M.14 (32.6)2 (13.3).111
    Interferon β-1a S.C.3 (9.3)0 (0)
    Glatiramer acetate8 (18.6)2 (13.3)
    Natalizumab4 (9.3)1 (6.7)
    Dimethyl fumarate2 (4.7)0 (0)
    Fingolimod3 (7.0)0 (0)
    Teriflunomide1 (2.3)3 (20.0)
    Rituximab1 (2.3)0 (0)
    Ocrelizumab0 (0)1 (6.7)
    IVIG1 (2.3)1 (6.7)
    No therapy6 (14.0)5 (33.3)
No. of LMCE foci1 (n = 33)1 (n = 8).292
2 (n = 8)2 (n = 4)
3 (n = 2)3 (n = 3)
LMCE shape (No.).637
    Nodular3616
    Linear75
    Plate-like124
T2 lesion volume (mean) (SD) (mL)16.0 (16.2)15.8 (11.4).965
Gd lesion volume (median) (IQR) (mL)0 (0–0)0 (0–0).097
  • Note:—EDSS indicates Expanded Disability Status Scale; I.M., intramuscular; S.C., subcutaneous; IVIG, intravenous immunoglobulin; Gd, gadolinium.

  • a P value represents differences between the patients with RRMS and SPMS. The differences between the groups were analyzed using the Fisher exact, Student t, Mann-Whitney U, or χ2 test.

  • b P values < .05.